Search

Displaying results 3781 - 3790 of 9129 in total
  1. Drug

    S-Hydroxycysteine

    go.drugbank.com/drugs/DB01915
    Experimental

    S-hydroxycysteine is a solid. This compound belongs to the alpha amino acids and derivatives. … It targets the proteins subtilisin BPN', glutathione S-transferase A1, glutathione S-transferase p, myelin P2 protein, and complement c3.

  2. Drug

    Ruserontinib

    go.drugbank.com/drugs/DB21555
    Investigational

    Ruserontinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Ruserontinib is a tyrosine kinase inhibitor. … Ruserontinib has a monoisotopic molecular weight of 443.25 Da.

  3. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    ApprovedInvestigational

    to provide passive immunization against RSV infection as an alternative means of protection. … Clesrovimab is a fully human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody targeted against the extracellular domain of the respiratory syncytial virus (RSV) fusion (F) protein.

  4. Drug

    Sotatercept

    go.drugbank.com/drugs/DB12118
    ApprovedInvestigational

    Sotatercept is an activin signalling inhibitor. … It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain.

    Synonyms: (HUMAN ACTIVIN RECEPTOR TYPE-2A PRECURSOR-(21-135)-PEPTIDYL)-THREONYLTRIGLYCYL-(HUMAN IMMUNOGLOBULIN HEAVY CONSTANT .GAMMA.1 FC FRAGMENT: (8-15)-HINGE-(A-100>V)-CH2-CH3 OF HOMO SAPIENS IGHG1*03), (123-, (HUMAN ACTIVIN RECEPTOR TYPE-2A PRECURSOR-(21-135)-PEPTIDYL)-THREONYLTRIGLYCYL-(HUMAN IMMUNOGLOBULIN HEAVY CONSTANT .GAMMA.1 FC FRAGMENT: (8-15)-HINGE-(A-100>V)-CH2-CH3 OF HOMO SAPIENS IGHG1*03), (123-
  5. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C. … The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C.

  6. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    RTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801. … The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD or ARMD).

  7. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). … This mechanism of action is similar to its predecessor [nusinersen], the biggest difference being their route of administration: nusinersen requires intrathecal administration, as does the one-time gene

  8. Drug

    Enlicitide

    go.drugbank.com/drugs/DB22580
    ApprovedInvestigational

    [L63795] Unlike the monoclonal antibody PCSK9 inhibitors ([evolocumab], [alirocumab]), enlicitide is administered orally as a once-daily tablet. … [L63795] Enlicitide is indicated as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), and was studied in

  9. Drug

    Nitroprusside

    go.drugbank.com/drugs/DB00325
    ApprovedInvestigational

    Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). … Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Loracarbef

    go.drugbank.com/drugs/DB00447
    ApprovedWithdrawn

    Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.